Upload
konstantinos-papadakis
View
217
Download
0
Embed Size (px)
Citation preview
8/18/2019 Bivalirudin for the Treatment of ST
1/30
BJ@I H HHH BJ@I H HHH --GH-@GH-@JH JH MM@ H@ H
@M G@ I
I@G: 27 #I@M 2011
..I/I/H230
© NICE 2011. All rights reserved.
http://nice.org.uk/guidance/ta230http://nice.org.uk/guidance/ta230
8/18/2019 Bivalirudin for the Treatment of ST
2/30
8/18/2019 Bivalirudin for the Treatment of ST
3/30
11 II
1.1 BJ@I H KH G @@ G H
HHH I@HG KH -GH-@JH M@ H
I M IHIG M HJH.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 3 of 30
8/18/2019 Bivalirudin for the Treatment of ST
4/30
22 H@M H@M
2.1 BJ@I (AL, G CM) G H IHGH 'G
HI@H I@H HHG I IHIG M
HJH (C"), @I HHG KH -GH-@JH M@
H (E") I M C"'. G H G LHG
H @ H KG J J 2009. GIM
IH HGHG (C) GHHG HH J@I GI@ GH
KH G @@.
2.2 A H H C, JM JG JH GGH KH J@I
HHH G @, K I MK H M. C JG
JHG HGG (@ @HG) @ IG H H IHIGH (H C"). JG JHG @@ HG GI G JG
(HH@ G), H @@ J H M HHGG H GH. F I@@ H@G
G HG HHG, G H C.
2.3 BJ@I G GH M >H IG. "H G J@@ J@G
H 250 K GHHIH @IH >H
IG. G J@I HHG I C" G
HJIG @IG 0.75 / M KH @@K H@M M HJIG IG H H 1.75 / M KH/I H @GH H
IH H I. IG M HI I H 4 IG H
C" H @@ . AH GGH H IG H 1.75 //
I, I G IG 0.25 //I M HI
4Q12 IG G @@@M GGM. AGGI 250 J@ G IG HH,
H IGH GH HHH KH J@I G O310.00 (BHG H@
I@M BF H 61), L@I A. CGHG M JM H GHHG
IG HH IH GIHG.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 4 of 30
8/18/2019 Bivalirudin for the Treatment of ST
5/30
33 IHI'G GIGG IHI'G GIGG
AG@ CHH (L A) G J GIHH M H IHI
J@I JK HG GIGG M H EJ +JK I (E+; L B).
3.1 IHI'G G @ J@I H KH
G @@ GH GHHM KH @MH H
H KH G @@. I@H KG I@HG KH -
GH-@JH M@ H H M C".
Clinical effectiveness
3.2 J H @@ HJGG J@I KG GHJ, I@-, G@-@, G I@HH GHIM.
!+"-A" H@ IH 3602 HHG KH E" H
M C" GHHM J@I KH IG @IG
@MH ""/""" HG. BH HHH G J G
@@. H@ G G H @GH 3 MG @@K-I H
J@@ H HG H.
3.3 HHG H J@I HHH I ( = 1800) J 0.75 /HJIG @IG J@I @@K M 1.75 //I IG HH
KG HI IHIH IH@ H @GH H H C". A H@ GH-
I@ G 0.25 //I KG I H 4 IG H
H I; 6% (105/1749) HHG J HG. A J@
( = 1.23 J@G) J@I KG IG HH (-H IG
J@I @MH ""/""" H J@G K G H H LH
H H J KGH H HH @J@). HHG H KH
@MH ""/""" H HHH I ( = 1802) J 60 "/
G M H EI HM C@M I@G
H H HHG KH E" I M C". A
@MH ""/""" H (H HRH L) KG J
KH HG GIM IH HGHG.
3.4 G H HHG K G@ GG H HHH IG, KH G@H@M
@ HHG H KH @MH ""/""" H I.
HH KG 61 MG H HHH IG. @H@M H
75% HHG K H 90% K KH. GHIM KG
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 5 of 30
8/18/2019 Bivalirudin for the Treatment of ST
6/30
IH H 123 GHG 11 IHG; 57% HHG K @@ EI
LH@M 3% H $. H IH I@H, 19 @H H GHIM
IG HM KHK GH 28 K @GH H @@K-I.
3.5 K HK M IHG: GH > JG
JGI@ JHG > @. M IHG K H
HG > JG JGI@ JHG: H (@@-IG H@HM
H@HM), H, HH JGG@ JGI@GH
G, GH. H GHH HGG KG @G GGGG. A@MGG
K IH H HH-H-HH I@H IHG K
GH 30 MG 1 M H C".
3.6 F H M IH > JG JGI@ JHG, J@IKG H H @IG @MH ""/""" H H 30 MG 1
M. " H HHH IG I 5.5% HHG > JG
JGI@ JH H 30 MG IH 12% H 1 M. F H M
IH > @, H KG GHHGH@@M GRH
( 0.0001) HK H HHH IG H 30 MG H 1 M. AH 30 MG,
> @ I 5.1% HHG H J@I I 8.8%
HHG H @IG @MH ""/""" H (H) I
( < 0.0001). AH 1 M, > @ I 5.8% HHG HJ@I I 9.2% HHG H H I ( < 0.0001).
3.7 F H GM IHG @@-IG H@HM H@HM, H
K GHHGH@@M GRH G HK HHH KH J@I
HHH KH @IG @MH ""/""" H. AH 1 M
@@K-I, @@-IG H@HM KG 3.5% H J@I I 4.8% H
H I ( = 0.037). 1-M GI@HG H@HM K
2.1% J@I 3.8% H ( = 0.005). F H HH-H-
HH I@H, 3-M @@-IG H@HM KG GRH@M @K ( = 0.03)
J@I (5.9%) H H H (7.7%).
3.8 H HHG K L H KG G@ HK
H HHH IG, G KG H H L GH, H
G K -GRH. A G@H@M H HHG H
J@I I HH JGG@ JGI@GH H H @IG
@MH ""/""" H I (7.2% KH 5.9% H 1 M), IH
HG KG H GHHGH@@M GRH.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 6 of 30
8/18/2019 Bivalirudin for the Treatment of ST
7/30
3.9 J@@ H M GHH HGG H 30 MG H 1 M KG H@
H J@I H @IG @MH ""/""" H IG.
!KJ, GHH HGG JHG I H J@I I
KH H RGH 24 IG C".
3.10 "JGHHG H @ HG JG JHG HK H
HHH IG, KH H HKG K JHG H J@I I
GRH@M I HG I-@H JG JHG ( < 0.0001).
RH@M K HMH JHG I H J@I I
(1.4%) H H @IG @MH ""/""" H I (3.9%;
< 0.0001).
3.11 II @MGG K GH @@-IG H@HM >@. F @@-IG H@HM, H GI@HG J@I K
JI@ GH GIIG HH K @MG, IH G K H
GHHGH@@M GRH. HH KH J@I KG GGH KH K
HG > @ H HHH KH @IG @MH ""/
""" H.
3.12 " H !+"-A" H@, @ H@ GG KG IG 5.9% (214/3597)
HHG J@@, KG @ @ GG KG IG GHHHG. " @@ H E@ @G @J@ @ GG
G LH. BIG H G@@ IG HHG I M C"
KH @ H@ GG, H IHI KG H @ H M IH
GHHGH@@M I@ H G @ H@ GG H
IHG GG. BJ@I KG GGH KH GHHGH@@M GRH
IH -GG GH () @, KH @HJ G 0.684 (95%
R HJ@ 0.507 H 0.922) KH @IG @MH
""/""" H.
Cost effectiveness
3.13 IHI GIHH @MGG HH @M
@ G @M H @MGG HH-@J@ H H
!+"-A" H@. @ G HK HG. RGH H G G-H
GHIHI HH JG H H@ IG H H GR @@K-I
(1 M H G G). H G@HG H G H @@K
H JHG H I: @JH @HG; @; > @;
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 7 of 30
8/18/2019 Bivalirudin for the Treatment of ST
8/30
G GH; M@ H; H JGI@GH; H.
H G I@ KH HK-GHH (@J/) J @ H IH
GIGIH GIJJ@ J 39-M N IG I@ M@ @H.
3.14 @ G @M H M H G @@-IG H@HM
HK H HK HHHG GJ H !+"-A" H@.
3.15 AG@IH @HJ @@ JH GG GH GI IG HG
K J H K H H !+"-A" HH-H-HH
I@H. @HJ GG HHH KH J@I KH
@IG @MH ""/""" H > @, @,
G GH, H M@ H, H JGI@GH
H K 0.643, 0.536, 1.057, 0.817, 1.124 0.710, GHJ@M. AJ@ LHM GGI H @ KG 11.26 MG. +@ GG IG
42.5% KG GGI.
3.16 CGHG J@I HHH K G H GHG H@ M,
H@ JGI@GH GH@ , HI@H HG,
H HHH-@H JG JHG @-H @@K-I.
H GHG HJH@ IG GGH HHH GHG K
G ! GHG. H IG KG G IG H!+"-A" H@. HH KH H GH LGJ @MH ""/"""
H (L) KG GGI H 70% GG K
@MH ""/""" H KG GH. GH HHH
KG G GRH KG HH H @. HHH
GH HH KH J@I KG O412 KH O573 @IG
@MH ""/""" H.
3.17 K IH@HM J@IG K IG H @ H H H H@ E"
JH: J@I 0.683 KG @ H RGH M @M 0.718 KG @
GIGIH M @. IH@HM J@IG K H JK
H @HHI. CGHG @H IHG K GIH H 3.5%.
3.18 " H G-G @MGG H J@I GHHM H H @IG
@MH ""/""" H GHHM IG H KG
HJ, KH HH@ GHG O12,843 O13,110, HH@ *AG 6.256
6.166, GHJ@M. IHI'G HGH GGHJHM @MGG
GK HH H GI@HG H @ K IGH H I HG,
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 8 of 30
8/18/2019 Bivalirudin for the Treatment of ST
9/30
@I G H @HJ GG H > @ H J@I
GHHM, @ LHM, HM @MH ""/""" H IG.
3.19 @GH GGHJHM @MGG GH H G-G 1-M @MGG
GK HH H J@I GHHM KG H (HH G, H KG GH-GJ
GK *A ) 9924 (99.2%) 10,000 "CE+ GI@HG H H O20,000
*A HG@.
3.20 H IHI GH 'LH G G' GJ@
IJI@ GGIHG (@M HRH IH L IG; 100% @
H@ GG; @H H@ GH@ GHM), H "CE+ KG
O4106 *A (KH GH O367
*AG 0.089). " @@ H GG, H J@I GHHM H.
Evidence Review Group comments
3.21 E+ H HH H G @ G J@I KH
@, IH H IG @ G H $ H. E+
G HH H IHI'G GIGG J HI IH
H @M J@@ +C.
3.22 E+ H HH H +C H H H @G G J@I
HHG I C" E". +C GH $
H HH -I@ KG IG GH HHG. H H
J@I I, HHG HH KH -I@ @K H
> JG JGI@ JHG H HG K H J
-I@ . G HH KG H G H H I.
!KJ, H KG GRH HH HK HHH I
-I@ ( = 0.1060). E+ H HH H G I@ K H
+C GI@HG KI@ SH H, J H @ -I@
GH $ H. +C @G GH $
H IG H@M @ H H @ H@ GG.
E+ HIH HH IG GG GH @ G @GG KH @ H
@ H@ GG, H RH G I @ J@I G
@@M H @K H H H +C.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 9 of 30
8/18/2019 Bivalirudin for the Treatment of ST
10/30
3.23 J@@ H E+ G HH H @ GHIHI @M M H
IHI GGG H G H G @.
HJH H KG H. E+ H HH H @
@G H G @HJ G JHG KH J@I HHH H @@ HHG
H J@I I, @GG KH HM I M
C". !KJ, HG GGIH H @H H @IGG H @.
3.24 E+ H HH H G H H H @ HHG @@ JHG G
IHI@@M L@IGJ, @HI @HM HM H. F L@, G
HHG I@ L H @ GH I H H@
H E". E+ H HH H G IH@HM J@IG @ H H
HHH GHHG, GI HH M @H-@H I@HM @
H @ G J M G GIJJ@ HK H HHH IG.H@HM HG G @HG @@K IG K H
@I H G-G @MGG. !KJ, H E+ H HH @M HJ
@H HG GGH KH H JGI@GH KI@ J
IJI@ H H GH HJGG J@I.
3.25 E+ HR G GGIG GG GHG H @,
IH HG M GRH H H GI@HG H @.
3.26 E+ KG GHGR HH H GI@HG H IHI'G @, K
GIGH HH J@I-G HJH HG @IG
@MH ""/""" H, K IGH H GGHJHM @MGG. BJ@I
H GG GH GGHJHM @MGG GG K H KG
HJ LGJ H @IG @MH ""/"""
H, H "CE+ J@I @K O5000 *A .
3.27 E+ IH L@HM @MGG H HH H IHI'G
@ KG IGH. G @I GGHJHM @MGG H @-H
J @ H GGGG H H IHHM I @-H
IHG HHG H IG. " HG @MGG H E+ I HH H
GHIHI H IHI'G @ H IG J H
G HH J IG J@I G GGH KH J GIJJ@
H @K GH H 1 M, H K@@ @KMG H @IG @MH
""/""" H J @ H NG.
3.28 E+ JGHH H @@K HK GGIG:
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 10 of 30
8/18/2019 Bivalirudin for the Treatment of ST
11/30
H H GGI 2 J@G J@I HH GH 1.23
H H IG GI@ H H I H H @@.
3.29 E+ I HH K H GGIH J@ IG KG
1.23 J@G H 2 J@G HH, J@I H H GHHM.
3.30 E+ GHH HH JGHH H H IG GI@ H
H H H @@, H H H@M
J@I @IG @@, KH @IG @MH ""/""" H @IG
GI@. E+ @G I HH H G @ H HHH KH
@IG @MH ""/""" H @IG GI@. HK
H@G J@I @IG GI@. RGH G J@I
@IG GI@ KH @@ @IG @IG L. G H@ G
J@I @IG GI@ KH @@ @IG .
3.31 E+ H H@G H KH H IHI'G GIGG
"CE H@M G@ 182 GI@ H HHH IH
M GMG KH C", K GK HH GI@ GI@HG
H@ HH I GH O162 KH @@. CGHG
GH@GH I K GHH H G@. E+ I HH
HG GH KG @ H H @IG @MH ""/"""
H I H @, J@I (J KH @@) KI@
GH-GJ. !KJ, J @H H H @HJ H J@I @IG
@@ JGIG GI@ @IG @MH ""/""" H G
H J@@.
3.32 FI@@ H@G @@ H J H IHI'G GIGG H E+
H, K J@@ KKK...I/I/A230
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 11 of 30
http://www.nice.org.uk/guidance/ta230http://www.nice.org.uk/guidance/ta230
8/18/2019 Bivalirudin for the Treatment of ST
12/30
44 CGCGH H H H JJ
4.1 AG@ CHH JK H H J@@ H @@ GH
HJGG J@I, J G J H HI -
GH-@JH M@ H (E") M IHIG
M HJH (C") H J@I @ H RHG J@I
M @ KH H H, HG K GH H, @@ G@GHG.
"H @G H H IH H HJ IG ! GIG.
4.2 CHH G H HI H H, H J
GIHH GH M H HH LHG @@ G@GHG H
@@ GG GMHG GGH KH E". CHH HH
J@I G @M IG H $ HH H HHG @G JI HG HI IG. "H KG H HH J@I G G H IG H
L IG H G@IH G G H GH. HH
LH GHGG H H I > @, K KG HIH
H HH RH J@I. C KH HI@HG,
J@I M I @GG H H JH
HHG.
Clinical effectiveness
4.3 CHH GIGG H J H @@ HJGG
J@I H KH G @@. "H HH H GI@HG
H G@ IH @ !+"-A" H@ (H H M IH >
@, H GM IHG @@-IG H@HM
H@HM) GK GHHGH@@M GRH JHG HHH KH
J@I J HHH KH @IG @MH ""/""" H. "
HI@ H H HH @@-IG H@HM KG 1.3% 1.8% @K H
J@I I H H H I H 1 3 MG @@K-I,
GHJ@M.
4.4 CHH GIGG KH G@ IHG H HG H
!+"-A" H@ LH HHG G $ @@ H.
CHH H @@ G@GHG HH H H@ G
@HHG: H @M J@I KH @MH ""/"""
HG, H KH @; H $, @ J C" J H @
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 12 of 30
8/18/2019 Bivalirudin for the Treatment of ST
13/30
8/18/2019 Bivalirudin for the Treatment of ST
14/30
4.8 CHH L@ H GG KM H J@I I, H HG
> JG JGI@ JHG GHH HGG K @K
HHG HH KH -I@ . @@ G@GHG L@
HH H G H IGH @@@M KM H -I@ KI@
I H H > JG JGI@ JHG. M GIGH HH H
I@H K J -I@ M H HG
K H, H G HG HH M J H H H >
JG JGI@ JHG. CHH H E+ HH H
KG HH HK -I@ H > JG
JGI@ JHG IH. @@ G@GHG @G L@ HH H G
H H H $ H GH -I@ ,
H@@M HG G H I H HJGG J@I @@
H. CHH KG GHGR HH G H IG -I@ HK H H@ $ @@ H KI@ H
GRH@M @H H JI@ IHG J@I.
4.9 CHH G KH H K M GIIG HHG K
KI@ LH H RH HHH KH J@I H H
IG. "H H @@ G@GHG HH HH@@M H H
GG@ H GJ J@I HG K H H HGH G @,
IH HH @HM H G HHG KI@ H G H GMHG M H GH GII H IGG HH HHH.
CHH KG GI HH GIIG I@ G@H H GG
H HGH HH@ H RH J@I.
4.10 CHH @G G H @HHG H H@. "H H HH H
KG @M G@ H@ HH H KG -@@ G KH G G G,
IH HH H GI@HG GIGH JH J@I.
CHH @I HH H KG GIRH J H GHH HH
J@I KG @@@M HJ H @MH ""/""" H @IG
, @ H @K HG > @G H@HM.
Cost effectiveness
4.11 CHH GIGG H IHI'G @ K H
H H GH HJGG G H I H@HM G KH
J@I HHH KH HHH KH @MH ""/"""
H @IG . "H H HH H G G, HHH KH J@I
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 14 of 30
8/18/2019 Bivalirudin for the Treatment of ST
15/30
KG H HJ @GG LGJ H HHH KH @MH
""/""" H @IG . G R IGH H H
HGH @GH GGHJHM @MGG.
4.12 CHH GIGG H IGHGG H IHI'G @. FGH H
CHH GIGG H HK-GH GHIHI H @: H@ GH,
K @@ JHG I@ I, @@K M GH GH H GH
H @H. IHI GH @ K H RGH GH G
1 M, H @ K H RGH GH G 3 MG. CHH KG
GHGR HH H GI@HG H 3-M @ K GGHH KH HG
H 1-M @. , H IGH H HGG IHI@@M
L@IGJ JHG KH H RGH GH H @ GIGH HH HG KG
JG@RH. IHI L@ HH H K HG JHG K I@ J @@. CHH H
HH H E+'G I@ H @ I GG. CHH
KG GHGR KH H H M H IHI HG @ G.
4.13 CHH H GIGG M IH GGIHG IG H @,
RGH@M J@ IG , G@M, @MH ""/""" H
H H I, H@M @ H@ GG. H G H J@
IG, H H @@ G@GHG HH HHH KH J@I KI@H @ H H H C", HH IGI@@M H H J@ KI@
IG. IG 1.23 J@G H H@ KG IG @I@H GH
HHH. CHH IGH KH J@G I@ G@H
H @@ G@GHG HH H 1 J@ K , G J@
KI@ IG M LH G. GHJHM @MGG KG IH M
H E+ H H @I 2 J@G GH 1.23 J@G H @, IH
H @ H M G H GI@HG. CHH KG GHGR KH H
KM HH J@ IG KG H H H @.
4.14 CHH G H GGIHG I H @MH
""/""" H IG H IHI'G @. "H H HH L,
K G H GH GH@M @MH ""/""" H, KG GGI H IG
73% @, HR 19% HRH, K G H @GH GH@M
@MH ""/""" H, @M 8.1%. CHH H
@@ G@GHG HH HG KG @@M IG L G H
JI @MH ""/""" H M MG, G @G
G @ KH HG IG HH HM @IHH H H HRH
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 15 of 30
8/18/2019 Bivalirudin for the Treatment of ST
16/30
HR. CHH H HH 100% IG HRH H
IHI'G GGHJHM @MGG G@@ H H "CE+, KH H
"CE+ J@I G H O1764 *A . CHH H
HH 100% HRH IG KG LH GH KG GHGR HH H
IG L H @ @H H H GH
HJGG J@I.
4.15 CHH G H GGIHG I @ H@ GG GH
H @. " H G-G @MGG, @ H@ GG KG GGI 42.5%
GG, @ KH $ H. A GGHJHM @MGG H IHI
K G H IG H 100% @ H G H GI@HG, KH
J@I H H HHH H. CHH KG
GHGR HH H @ GI@HG K IGH H G GG GH.
4.16 CHH GIGG H GI@HG H GGHJHM @MGG,
K 100% HRH IG KH H GGIHG 100%
@ H@ GG I@ @H GH@ GHM HG HH KH
J@I HG HH KH @MH ""/""" HG. " HG
@MGG, K KG G M H IHI H H GH
IJI@ G J@I, H "CE+ G H O4106 *A. CHH H HH HG IJI@ GH KG @@@M
I@GH, IH H HH H "CE+ I KH HG @MGG KG GH@@ K@@
KH H @@M G H GH-HJ IG !
GIG.
4.17 CHH @I H GIGG M H H IGHGG H
IHI'G G G, K HHH KH J@I H
HHH KH @MH ""/""" H @IG (HH G, KG @GG
GH@M HJ) HH H GI@HG H @ IGH H H
JIG GGHJHM @MGG. CHH @I HH H @ G
GGH KH JM @K G IHHM HH J@I
GI@ H HHH I@HG KH E" I
C".
4.18 I@HG GGIG K G H M H H G@.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 16 of 30
8/18/2019 Bivalirudin for the Treatment of ST
17/30
Summary of Appraisal Committee's key conclusions
A230 AG@ HH@: BJ@I H HHH -GH-
@JH M@ H
H
$$M @IGM @IG
BJ@I H KH G @@ G H
HHH I@HG KH -GH-@JH M@ H (E")
I M IHIG M HJH (C").
1.1
CIH CIH HH
C@@
HHG, @I
H J@@HM
@HHJ
HHHG
BJ@I G @M IG H $ H HHG
@G JI HG HI IG. BJ@I G G
H IG H L ( @MH ""/""" H)
IG H G@IH G G H GH.
HH LH GHGG H H I >
@, K KG HIH H HH RH
J@I. C KH HI@HG, J@I M
I @GG H H JH
HHG.
4.2
H@M H@M
G RHG
H H@M
!K JHJ G
H H@M HG
HH@ H
GRH
GIGHH@ H @H-@H
RHG?
M IH > @ H GM
IHG @@-IG H@HM H@HM GK
GHHGH@@M GRH JHG HHH KH
J@I J HHH KH @IG @MH ""/
""" H. " HI@, @@-IG H@HM KG 1.3%
1.8% @K H J@I I H H H
I H 1 3 MG @@K-I, GHJ@M.
4.3
H G H GH
H HHH
H HKM
H H?
BJ@I G IG G HI@H I@H HHG KH
E" I M C".
2.1
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 17 of 30
8/18/2019 Bivalirudin for the Treatment of ST
18/30
AJG HG J@I I GHH
HGG KH H RGH 24 IG C" H H
H I
4.7
EJ @@ HJEJ @@ HJGGGG
AJ@@HM, HI
I@HM
J
A G@ H@ (!+"-A") H J G. "H
KG -@@ H@ KH G G G. !KJ, H
CHH @I HH H KG GIRH J H
GHH HH J@I KG @@@M HJ H
@MH ""/""" H @IG .
4.10
+@J H
@ @@H H !
" H $, @ J C" J H @ GG GH H
H H@. IG H @ GG GH, KH@ GG, IG H GG GH @.
! H I GG GH @ GJ KH
J@I H H@ M HHIH $ H.
CHH H HH G@ HG -GG GH
@ I@ LH $ @@ H G H
H@.
" H H@ GIGHH@ I HHG K HH KH
-I@ IH HG G H H H
$. CHH KG GHGR HH G H IG
-I@ HK H H@ $ @@
H KI@ H GRH@M @H H JI@ IHG
J@I.
4.4
4.54.8
HHG
H M H
J
CHH GIGG H IG J@I H
KH G GI@ G G H G
@@. "H KG GHGR HH HG HHH H G
IHG H H IHGH J@I H M H H HG G@.
4.7
A H M
@@@M @JH
GIIG K
H G J
H@
HJGG?
CHH KG GI HH GIIG I@
G@H H GG H HGH HH@ H RH
J@I.
4.9
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 18 of 30
8/18/2019 Bivalirudin for the Treatment of ST
19/30
EGHH H GN
H @@
HJGG
@I GHH
GIH J
M IH > @ H GM
IHG @@-IG H@HM H@HM GK
GHHGH@@M GRH JHG HHH KH
J@I J HHH KH @IG @MH ""/
""" H. " HI@, @@-IG H@HM KG 1.3%
1.8% @K H J@I I H H H
I H 1 3 MG @@K-I, GHJ@M.
4.3
EJ GH HJEJ GH HJGGGG
AJ@@HM
HI J
IHI GIHH @MGG HH
@M @ G @M H @MGG
HH-@J@ H H !+"-A" H@.
3.13
HHG
I
@IG@HM
GGIHG
IHG H
@
CHH G HH H GI@HG H @
K GGH KH JM @K G
IHHM.
4.17
"H
@H-@HI@HM--@
RHG IH@HM
J@IG
!J M HH@
GRH
GIGHH@ @H-
@H RHG
HR HHK H @I
H @,
K J HM
G?
K GGIG G IH @H-@H I@HM--
@ J@IG HH K HIH H @JH. @H-@HRHG K HR HH K H @I H
@.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 19 of 30
8/18/2019 Bivalirudin for the Treatment of ST
20/30
A H GR
IG @
K H
H@M G
HI@@M GH
HJ?
CHH KG GI HH GIIG I@
G@H H GG H HGH HH@ H RH
J@I.
4.9
H H M
JG GH
HJGG?
H H GH HJGG H @ G H
I H@HM G KH J@I HHH
KH HHH KH @MH ""/""" H @IG
.
4.11
GH @@M GH-
HJGG
GHH (J G
"CE+)
" H G G, HHH KH J@I H H
H HH H KG H HJ @GG
LGJ H HHH KH @MH ""/""" H
@IG .
4.17
AH@ HG HAH@ HG H H IH H IH
HH GG
GG (+)
HH GG GG K GIHH.
E--@
GHG
E--@ GHG K H GIGG.
EI@HG
GHG
G@ J@I
>IHG
I@HG GGIG K G H M H H G@. 4.18
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 20 of 30
8/18/2019 Bivalirudin for the Treatment of ST
21/30
55 "@HH"@HH
5.1 HM HH H @G AGG@M GH !@H @
JG J GGI HG H H ! E@ @G
@H "CE H@M G@ I. "CE H@M
G@ G IG I HHH, H H@M, H !
IGH IGI@@M J I GIG H KH 3 HG H
I I@G. " H DHH !@H GGIG JH H H
3-H I H, H@G K@@ J@@ H "CE KGH.
H G "CE H@M G@ I I, HHH H
H@M, GG I GI@ @@@M.
5.2 "CE G J@ H@G H @ GHG IH HG I H H(@GH @K). G J@@ I KGH (KKK...I/I/
A230).
CGH H@H H H GHH H H@ @@ GJG GHG
GGH KH @HH.
AIH GIH H @@ H.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 21 of 30
http://www.nice.org.uk/guidance/ta230http://www.nice.org.uk/guidance/ta230http://www.nice.org.uk/guidance/ta230http://www.nice.org.uk/guidance/ta230
8/18/2019 Bivalirudin for the Treatment of ST
22/30
66 +@H "CE I+@H "CE I
Published
-I M HM MGG. "CE HJH@ I I 377 (2011).
AJ@@ KKK...I/I/"377
GH@ E". "CE @@ I@ 94 (2010). AJ@@
KKK...I/I/C94
GI@ H HHH IH M GMG KH IHIG M
HJH. "CE H@M G@ I 182 (2009). AJ@@
KKK...I/I/A182
DI-@IH GHHG H HHH M HM GG. "CE H@M G@
I 152 (2008). AJ@@ KKK...I/I/A152
": GM JH. "CE @@ I@ 48 (2007). AJ@@ KKK...I/
I/C48
B@@ @GHM KH KHIH GHH HH HH H I@HG
@. "CE HJH@ I I 74 (2004). AJ@@
KKK...I/I/"74
CM : M@ IG GHM H GG H
M@ H. "CE H@M G@ I 73 (2003). AJ@@
KKK...I/I/A73
I H IG M HM GHHG. "CE H@M G@ I 71 (2003).
AJ@@ KKK...I/I/A71
Under development
"CE G J@ H @@K I (H@G J@@ KKK...I):
@ H HHH IH M GMG (AC). "CE H@M G@.
I@H H H R.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 22 of 30
http://www.nice.org.uk/guidance/ipg377http://www.nice.org.uk/guidance/cg94http://www.nice.org.uk/guidance/ta182http://www.nice.org.uk/guidance/ta152http://www.nice.org.uk/guidance/cg48http://www.nice.org.uk/guidance/cg48http://www.nice.org.uk/guidance/ipg74http://www.nice.org.uk/guidance/ta73http://www.nice.org.uk/guidance/ta71http://www.nice.org.uk/http://www.nice.org.uk/guidance/ta236http://www.nice.org.uk/guidance/ta236http://www.nice.org.uk/http://www.nice.org.uk/guidance/ta71http://www.nice.org.uk/guidance/ta73http://www.nice.org.uk/guidance/ipg74http://www.nice.org.uk/guidance/cg48http://www.nice.org.uk/guidance/cg48http://www.nice.org.uk/guidance/ta152http://www.nice.org.uk/guidance/ta182http://www.nice.org.uk/guidance/cg94http://www.nice.org.uk/guidance/ipg377
8/18/2019 Bivalirudin for the Treatment of ST
23/30
77 ++JK IJK I
7.1 I HG H@M K@@ G JK #I@M 2014.
I ELIHJ K@@ KH H H@M GI@ JK
G H H M "CE, GI@HH KH GI@HG
HHG.
AK D@@
C ELIHJ
#I@M 2011
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 23 of 30
8/18/2019 Bivalirudin for the Treatment of ST
24/30
AL A: AAL A: AG@ CHH G, "CE >H HG@ CHH G, "CE >H H
A Appraisal Committee members
AG@ CHHG GH JGM HHG "CE. G H
3-M H. A @GH H CHH G K H H H GIGGG HG G@
G @K. I AG@ CHHG, KH J . E
AG@ CHH HG H, LH D K H HG. E
CHH GG HG K @GH H@G, HG H J HK
CHHG.
CHH G G H @ M HGHG H H@M H G. " H G
G H G SH HGH, H G L@I HH IH HHG@.
IHG AG@ CHH H, K @I H G H G K
HH H @HG HGHG, GH H "CE KGH.
D $HM A@D $HM A@ + CGI@HH GMHGH/DH CH 'G H@
!@H, JGHM GH
D D@ BMD D@ BM CGI@HH "HGJ C AGHG, R@
!GH@G ! IGH
DDJ C@J C@ M
D M CD M C HI, @ IG, KM @ , JGHM GH
+ D+ DJJIL-@@GIL-@@G DH, I@ @M AJM EI, BD, L
GG +@ A E@@HHGG +@ A E@@HH H GG G !@H, JGHM HH
D A@ !D A@ !MMLL + !@H EG, JGHM J@ H @
GG CHGG CHM #GM #G GG M C , JGHM H AKG
GG M GG M GG CJGI@ , *IG JGHM B@GH
CGI@HH MG, B@GH CHM !GH@
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 24 of 30
8/18/2019 Bivalirudin for the Treatment of ST
25/30
D EI @D EI @ DIHM +@ DH I@ !@H, H EGH HH !@H AIHHM,
KGH@ I M
+IH @J+IH @J-@@G-@@G ! IG/*I@HM "JH I@ JG, +M@ DM
!GH@
GG $H GG $H MM GG !@H EG, JGHM GH
D D@@ MD D@@ M M
E@@ +I@E@@ +I@ DH, ! BGH@
D D H @H @MM CGI@HH MG, CH@ GH JGHM !GH@G ! FIHIGH
D I HD I H CGI@HH I@ !@H , H GH @G JG
CGG , H
GG AK HGG AK HJJGG C AG@ CHH C, GG I@ !@H, JGHM
B
GG GG I@ I@ II GG !@H EG, BI@ JGHM,
D #IH D #IH @@ M
B NICE project team
E H@M G@ G GG H H GGH @H H@M
@MGHG (K H G H@ @G H G@), H@ JG >H .
D !@ HD !@ H @
# !@# !@ @ AJG
F F >H
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 25 of 30
8/18/2019 Bivalirudin for the Treatment of ST
26/30
AL B: IG AL B: IG J G J G M H CHHM H CHH
A EJ +JK I (E+) H HG G@ KG M @ !@H
+@H +G (!A++):
G E, FHN@ , EJG , H @. BJ@I H HHH -GH @JH
M@ H. 2011
B @@K GHG H H JHH H HH HG G@ G GI@HG
HHG. M K JH H H H H G. GHG @GH " K
@G JH H KHH GIGGG. GHG @GH "" J H LH JKG
J@I H HHH I@HG KH -GH @JH M@ H I
IHIG M HJH M J KHH GHHH H H CHH.GHG @GH ", "" """ J H HIHM H @ GH H R@ G@
HH.
" IHI/GG
G CM
"" GG@/G@GH HH/ IG:
!H C HG $
!EA+ $
BHG AGGH IG C C
BHG CJGI@ "HJH HM (BC")
BHG CJGI@ HM
BHG !H FIH
M C CJGI@ HM +M@ C@@ IG
+M@ C@@ MGG
""" H GI@HG:
DHH !@H
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 26 of 30
8/18/2019 Bivalirudin for the Treatment of ST
27/30
@G AGG@M JH
" CHH GHG ( H J KHH J KHIH H H @):
BHG H@ FI@M
CGG IH AG@G J
DHH !@H, @ JG I@ HM H "@
!@H "JH H@
E@ @@M
@LH$@
& D
R AJHG
H@ "GHHIH !@H +G !@H @M AGGGGH
@ !@H & +@H +G R@ (!A++)
C @@K JI@G K G@H @@ G@GH HH LH HG
H -IHI/GG GI@HG HHG. M J H LH
G@ JK BJ@I H HHH -GH @JH M@ H M
J @ J H H CHH.
D D@ B@, CGI@HH @GH, H M BHG CJGI@
"HJH HM Q @@ G@GH
D $, CGI@HH "HJH@ C@GH, H M @G AGG@M
JH Q @@ G@GH
@H @, AIH CM MG AJ IG HH, H M
BHG AGGH IG CJGI@ C - @@ G@GH
# @@, H M !H C HG $ Q HH LH
D +GHHJG H @@K IHI/GG HH CHH HG. M
HIH @M K G M H CHH H @M GR GGIG H
HI@ IM.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 27 of 30
8/18/2019 Bivalirudin for the Treatment of ST
28/30
G CM
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 28 of 30
8/18/2019 Bivalirudin for the Treatment of ST
29/30
AIH HG IAIH HG I
"CE H@M G@ I G IH H IG K LGH G HHHG
H ! E@ @G.
G I KG J@ IG H "CE G@ H@M G@ GG.
J I GIM HG I HHG G. @G H @ MI IH H
I H H H IH H J H G G @G J@@.
IIGG@HMGG@HM
G I GHG H JKG "CE KG J H H I@ GH HJ J@@. !@H GG@G LH H H H I@@M H IH K
LG H @@ >IH. !KJ, H I G H J H JI@
GG@HM @H GG@G H GG H H H IGHG
H JI@ HH, GI@HH KH H HH / I .
"@HH HG I G H GG@HM @@ GGG / JG.
CGGG JG HH H G H GG@HM H @H H
I, H @@ HLH, @H H IHG H J I@KI@ GH H J H H I@HM HIHM. H HG I GI@ HH
KM K KI@ GGHH KH @ KH HG IHG.
CCMHMH
P H@ "GHHIH !@H C@@ EL@@ 2012. A@@ HG GJ. "CE MH
H@ K@ JH G GHIM, M I IH@
H--RH IGG. IH M @ GHG,
@ IGG, G @@K KHIH H KHH GG "CE.
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
© NICE 2011. All rights reserved. Page 29 of 30
http://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidancehttp://www.nice.org.uk/guidance/ta230/informationforpublichttp://www.nice.org.uk/guidance/ta230http://www.nice.org.uk/guidance/ta230http://www.nice.org.uk/guidance/ta230/informationforpublichttp://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance
8/18/2019 Bivalirudin for the Treatment of ST
30/30
Accreditation
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)
http://www.nice.org.uk/http://www.nice.org.uk/